However, because of the availability of a large range of well-tolerated BTK inhibitors with clinical efficacy in B cell malignancies, inhibition of BCR signaling as a therapeutic target for autoimmunity is mainly focused on targeting BTK [12], while PLCγ2 is currently not pursued. Here, BCR is linked to Autoimmunity.